Home » Topics » BioWorld

BioWorld
RSS

PLAN FOR FDA FEES PICKS UP SUPPORT

Aug. 11, 1992

AMEX INDEX SLIPS

Aug. 11, 1992

APPOINTMENTS AND ADVANCEMENTS

Aug. 11, 1992

CENTOCOR, LILLY FINALIZE ALLIANCE

Aug. 11, 1992

ARRIS RAISES $15.5 MILLION

Aug. 11, 1992

GENETIC STRATEGY TO RESURRECT CHESTNUT TREE

Aug. 10, 1992

IXSYS, BIOSITE TEAM TECHNOLOGIES

Aug. 10, 1992

GENTA FILES IND FOR PSORIASIS TREATMENT

Aug. 6, 1992

SKB TO SELL PCR-BASED TEST FOR TB

Aug. 6, 1992

NEW COMPANY TO EXPLORE COMPLEMENT INHIBITOR

Aug. 6, 1992

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...